Who We Are

Object Pharma is an innovative fully integrated biopharma company dedicated to the development of new therapies for the treatment of mental illness. Our first indication is Major Depressive Disorder (MDD).

Object Pharma has a revenue generating division, called Metabiologics, that sells critical reagents to the botulinum neurotoxin community. These sales have allowed Object Pharma to self-fund the preclinical stage of our first product candidate, OP01.